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 We developed a 2D/3D hybrid model
of cell colony growth under cell
cycle inhibition.
 Our model integrates physical and
physiological components of the
cell cycle.
 Our model captures population-level
emergent properties.
 Our model elucidates the character-
istics of cell cycle-inhibiting drug.
 Our model shows how cell colony
morphology affects cell cycle inhibi-
tion efﬁcacy.
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a b s t r a c t
Cyclin-dependent kinases (CDKs) are vital in regulating cell cycle progression, and, thus, in highly
proliferating tumor cells CDK inhibitors are gaining interest as potential anticancer agents.
Clonogenic assay experiments are frequently used to determine drug efﬁcacy against the survival
and proliferation of cancer cells. While the anticancer mechanisms of drugs are usually described at
the intracellular single-cell level, the experimental measurements are sampled from the entire
cancer cell population. This approach may lead to discrepancies between the experimental observa-
tions and theoretical explanations of anticipated drug mechanisms. To determine how individual cell
responses to drugs that inhibit CDKs affect the growth of cancer cell populations, we developed a
spatially explicit hybrid agent-based model. In this model, each cell is equipped with internal cell
cycle regulation mechanisms, but it is also able to interact physically with its neighbors. We model
cell cycle progression, focusing on the G1 and G2/M cell cycle checkpoints, as well as on related
essential components, such as CDK1, CDK2, cell size, and DNA damage. We present detailed studies of
how the emergent properties (e.g., cluster formation) of an entire cell population depend on altered
physical and physiological parameters. We analyze the effects of CDK1 and CKD2 inhibitors on
population growth, time-dependent changes in cell cycle distributions, and the dynamic evolution of
spatial cell patterns. We show that cell cycle inhibitors that cause cell arrest at different cell cycle
phases are not necessarily synergistically super-additive. Finally, we demonstrate that the physical
aspects of cell population growth, such as the formation of tight cell clusters versus dispersed
colonies, alter the efﬁcacy of cell cycle inhibitors, both in 2D and 3D simulations. This ﬁnding may
have implications for interpreting the treatment efﬁcacy results of in vitro experiments, in which
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treatment is applied before the cells can grow to produce clusters, especially because in vivo tumors,
in contrast, form large masses before they are detected and treated.
& 2014 The Authors. Published by Elsevier Ltd.
1. Introduction
One of the hallmarks of cancer is uncontrolled proliferation, a
consequence of loss of control over the normal cell cycle (Hanahan
and Weinberg, 2011). The mammalian cell cycle is a sequence of
complex processes that ensures the faithful replication of DNA and
the equal division of identical chromosomal copies between two
daughter cells. The sequence of these processes is tightly regu-
lated, thereby guaranteeing that the initiation of later events (such
as physical cell division) is preceded by the completion of earlier
events (such as cell organelle duplication or DNA synthesis). The
cell cycle is usually divided into four general phases: G1 (gap
phase), in which a cell increases in size and duplicates its
organelles; S (synthesis phase), during which DNA is replicated;
and G2 (gap phase), which involves cell preparation for chromo-
some separation and physical division into two offspring cells in
the M (mitosis) phase. The successful completion of the cell cycle
necessitates that these separate phases take place at the right
sequence and at the right time. If a cell attempts mitotic division
before its chromosomes have been fully replicated, the daughter
cells will inherit incomplete DNA. Conversely, if the cell undergoes
several rounds of DNA replication between mitoses, it will contain
multiple copies of chromosomes. Moreover, a cell requires a
sufﬁcient interval between two consecutive cell divisions for it
to double its mass and organelles; unless such a condition is
satisﬁed, daughter cells become progressively smaller. In all of
these cases, the emerging cell subpopulation loses its normal
characteristics, and may acquire genomic or chromosomal instabil-
ity (Malumbres and Barbacid, 2009).
Among the mechanisms that cells have developed to ensure
the appropriate completion of the cell cycle are cell cycle check-
points. These can actively halt progression through the cycle until
the critical events of a particular cell cycle phase are ﬁnalized.
These checkpoints can also respond to cell DNA damage by
arresting the cell cycle, thereby providing time for DNA repair.
Several cell cycle checkpoints respond to speciﬁc forms of stress,
and impose arrest at speciﬁc points in the cell cycle (Alberts et al.,
2008). For example, a checkpoint in the G1 phase ensures that a
cell reaches an adequate size before it enters the S phase; small
cells in a cell culture remain longer in the G1 phase, a behavior
that enables the cells to continue growing (Zetterberg and Larsson,
1991). The G2 checkpoint suspends the cell cycle if extensive DNA
repair is required before a cell can initiate mitosis (Gould and
Nurse, 1989). The speciﬁc checkpoint in the M phase, called the
spindle assembly checkpoint, can delay the cell cycle to avoid the
erroneous segregation of chromosomes (Mikhailov et al., 2002;
Rudner and Murray, 1996).
Cyclin-dependent kinases (CDKs), a family of protein kinases,
are critical regulators of cell cycle progression (Malumbres and
Barbacid 2009; Morgan 1997). The activity of CDKs is modulated
by several cyclins and functional inhibitors (e.g., Ink4, Cip, and Kip)
(Weinberg, 2007). Among the 13 CDKs expressed in human cells,
CDK2, CKD4, and CKD6 are involved in the interphase, and CDK1 is
involved in mitosis (Malumbres and Barbacid, 2009). The cyclins
associated with particular CDKs activate CDK catalytic abilities,
and together are responsible for passing through the cell cycle
checkpoints. Tumor-associated mutations frequently deregulate
certain CDK–cyclin complexes, resulting in either continued pro-
liferation or unscheduled reentry into the cell cycle (Lapenna and
Giordano, 2009). This opens up possibilities for CDK inhibitors as
relevant drug candidates for cancer therapy (Lapenna and
Giordano, 2009; Fu et al., 2011; Kreahling et al., 2012; Parry
et al., 2010). The selective inhibition of CDKs may limit the
progression of a tumor cell through the cell cycle and facilitate
the induction of an apoptotic pathway. Speciﬁc CDK–cyclin com-
plexes that are modulated by CDK inhibitors may also be respon-
sible for maintaining a quiescent state in different cell populations
(Malumbres and Barbacid, 2009).
This paper focuses on two CDKs—CDK1 and CDK2—each
involved in the control of cell cycle checkpoints. During the G1
phase, CDK2 forms a complex with the E-type cyclins (E1 and E2)
that enables transition from the G1 to the S phase (Weinberg,
2007). The CDK2–cyclin E complex can also prevent cells from
passing the G1 checkpoint if it is diminished (Koff et al., 1992;
Koledova et al., 2010). Upon entering into S phase, the E-type
cyclins are gradually replaced by A-type cyclins (A1 and A2) that
form complexes with CDK2 and enable progression through the S
phase until the A-type cyclins start forming complexes with CDK1,
which allows the cell to move to the G2 phase (Weinberg, 2007).
However, passage through the G2-phase checkpoint is also con-
trolled by the phosphorylation and dephosphorylation of CDK1 via
WEE1 and CDC25 (O'Connell et al., 1997; Raleigh and O'Connell,
2000). Moreover, CDK1 stimulates the mechanism for repairing
DNA double-stranded breaks (Ira et al., 2004), which enables the
cells to reduce their DNA damage before entering into M phase. In
the G2 phase the A-type cyclins are replaced by the B-type cyclins
(B1 and B2), and the CDK1–cyclin B complexes are responsible for
the transition from G2 to M phase (compare Fig. 8.12 in (Weinberg
2007)).
We model the CDK-regulated cell cycle in individual cells in a
simpliﬁed way. We do not consider separate cyclins, but do model
the CDK–cyclin complexes together, as well as the total amounts of
both CDKs, because our main goal is to investigate the inﬂuence of
CDK1 and/or CDK2 inhibition on cell population behavior. There
are more detailed models of CDK–cyclin kinetics (Gerard and
Goldbeter, 2009; Gerard et al., 2013; Tyson and Novak, 2008);
however, they do not consider spatial interactions between cells in
large populations, as we do in this paper. Therefore, to build a
model that incorporates both intracellular and intercellular
aspects of the cell-cycle control, we use a single-cell-based off-
lattice hybrid model in which each cell is equipped with an
individually regulated cell cycle, and at the same time the cells
can interact physically with one another. To our knowledge, only
the model developed by Powathil et al. (2012, 2013) addresses
both these aspects. However, our model uses a different mathe-
matical framework to model individual cell dynamics and focuses
on different components of the cell-cycle regulation mechanisms.
In this paper, we discuss mainly the 2D version of our model as an
analog of an experimental clonogenic assay, and the simulated
results may be compared to those derived from typical 2D in vitro
experiments, as we show in Section 4.
The clonogenic survival assay is an in vitro experimental
technique that can be used for verifying whether a potential
anticancer agent has therapeutic effects. It is used to evaluate
whether tumor cells can sustain indeﬁnite proliferation and
thereby form multicellular clones (Franken et al., 2006; Munshi
et al., 2005). In this experimental setting, cells are cultured on 2D
plates in a medium that contains the nutrients necessary for cell
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growth and survival. A constant concentration of the anticancer
agent is added to the culture (the medium is changed periodically
to keep conditions uniform). After a speciﬁc period, the cells are
ﬁxed, often stained, or counted. The results are usually reported
after normalization using the cell number of the nontreated
(control) cell culture. The ﬁndings may also be interpreted as cell
growth inhibition relative to the growth of control cells. A similar
protocol is used in our computational model, but for simplicity, we
model only a small but representative part of an entire plate,
which is typically visible under a microscope.
2. Model
We use an off-lattice hybrid model of growing cell colonies. In
its 2D version, the model is a computational analog of in vitro
clonogenic assays (Sakaue-Sawano et al., 2008; Tyson et al., 2012),
whereas the 3D version of the model is an analog of a typical
multicellular spheroid culture (Godugu et al., 2013; Shaw et al.,
2004). We model cells as individual entities: each equipped with
an individually regulated cell cycle, individually controlled cell
size, cell migration, cell–cell interactions, and individually deﬁned
cell response to environmental cues including the drugs inhibiting
CDKs. These conditions enable us to investigate the emergent
properties of an entire cell population. We incorporate sufﬁcient
morphological and physiological details about a single cell in the
model to compare the model results with experimental data, but
the cell representation is simple enough; thus, we can simulate
the behavior of thousands (or more) of cells under a reasonable
computational time. Each cell is mathematically represented by a
disk and speciﬁed by a pair of variables (x, a), where x is the center
of the disk and represents the physical location of a cell, and a is
the cell radius (the reference cell radius is a0¼5 μm). Both of them
can dynamically adapt during the simulation. Cell location changes
during cell movement, and cell radius changes during cell growth
or shrinkage. Simultaneous consideration of both these variables is
necessary to impose the volume exclusivity condition between
cells. This is critical because cells compete for limited space during
colony expansion. Each in silico cell is equipped with an individual
cell cycle control mechanism that is deﬁned by a set of ordinary
differential equations. These features enable us to trace the cell
progression through cell cycle phases, and to determine the roles
of speciﬁc molecules (CDK1 and CDK2) in cell cycle control. We
ﬁrst describe the cell cycle control model, and then the mechanics
of individual cell growth and migration, which are crucial to the
development of tumor cell colonies under CDK inhibition. The
pseudo-code of the fully integrated algorithm of cell cycle regula-
tion, growth, migration, and cell–cell interactions is presented in
Table 1.
2.1. Cell cycle regulation
Cell cycle regulation and control mechanisms are biologically
complex and comprise many interconnected components. In this
paper, we focus on cell cycle checkpoints and the roles of CDK1
and CDK2 in cell cycle regulation. Both kinases form complexes
with the appropriate cyclins that are crucial in facilitating passage
through cell cycle checkpoints. During the G1 phase, the newly
born cell needs to ﬁrst increase its volume and the amounts of all
proteins necessary to survive and progress through the cell cycle.
Two factors, cell size and the amount of CDK2–cyclin E complexes,
determine whether a cell is ready to pass the G1 checkpoint and
move on to the S phase. CDK2 can be inhibited from forming this
complex, which may prolong the G1 phase indeﬁnitely; we regard
this phenomenon as G1 arrest. For the cells that pass the G1
checkpoint, CDK1 stimulates DNA repair (by the homologous
recombination discussed below) and, when inhibited, signiﬁcantly
slows down the DNA repair process in the S and G2 phases. CDK1
also undergoes phosphorylation by the nuclear kinase WEE1
(at Tyr15 of CDK1) that is affected by the levels of DNA damage.
The increased phosphorylated CDK1 prevents a cell from passing
the G2/M checkpoint. The cell then stays in the G2 phase, which
allows for DNA repair and, in turn, diminishes the amount of
phosphorylated CDK1. Both the inhibited and phosphorylated
CDK1s are subsets of CDK1, and they are not mutually exclusive.
Some of the DNA repair processes are cell cycle speciﬁc; such
processes include the homologous recombination (HR, amending
double-stranded DNA breaks by using similar or identical mole-
cules of DNA as templates) that is more pronounced in the S and G2
phases and the nonhomologous end-joining (connecting open ends
in double-stranded DNA breaks without any template) that is active
mostly in the G1 phase (Branzei and Foiani, 2008). The other
mechanisms of DNA repair that are active throughout the entire
cell cycle are base excision repair, which ﬁxes small, nonhelix-
distorting base lesions by removing damage bases, and nucleotide
excision repair, which restores bulky helix-distorting lesions by
scanning through damage regions (Branzei and Foiani, 2008; Curtin,
2012). We also recognize the importance of spatial interactions
between cells, especially cell volume exclusivity; thus, we trace the
size of each cell (cell radius) during all the phases of the cell cycle.
The full list of model variables is given in Table 2, the governing
equations in Table 3, and the model parameters and their values in
Table 4. Some of these equations are phase independent because
the underlying kinetics occur throughout the entire cell cycle, and
the others take different forms in different cell cycle phases
because they describe phase-speciﬁc mechanisms. However, all
of the equations are written in Table 3 in a uniﬁed format. Since
the newly born cell upon division of the mother cell inherits half of
its mass and protein contents, the total amounts of CDK1, CDK2,
and WEE1 need to be increased during the G1 phase for the cell to
Table 1
Pseudo-code of the full algorithm of cell cycle regulation, growth, migration, and
cell–cell interactions.
Program cell cycle update for Δt
for i¼1 to Number_of_cells
Update all Nprotein
Update Q, P
Update ai
end of for
for i¼1 to Number_of_cells
Calculate repulsive forces based on updated ai
Update location
end of for
Neighbor search
for i¼1 to Number_of_cells
Apply growth rate compromise algorithm based on ai to settle aiﬁnal
ai¼aiﬁnal
end of for
for i¼1 to Number_of_cells
Update cell phase based on new variables
end of for
Calculate motility forces for each cell
for i¼1 to Niteration
Update locations of all cells following the motility forces
for Δt /Niteration
Calculate repulsive forces based on ai
Update location
Neighbor search
end of for
for i¼1 to Number_of_cells
if cell qualiﬁes for the cell division
Replace with two daughter cells
end of if
end of for
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function properly. We follow a simple kinetics of protein produc-
tion and degradation where the total amount of each protein is
normalized to 1 (Eqs. (1–3)), and the rCDK1, rCDK2, and rWEE1 denote
the net increase rate (arising from combining both production and
degradation rates) for CDK1, CDK2 and WEE1, respectively. Simi-
larly, by combining the forward and reverse reaction rates and
normalizing the total amounts of CDK inhibitors, their kinetics is
described by Eqs. (4–5) with the net increase rates rCDK1i and rCDK2i,
respectively. The kinetics of the CDK2–cyclin E complex formation
in the G1 phase is controlled by the amount of uninhibited CDK2
(i.e. NCDK2–NCDK2i) with net increase rate rCDK2E (Eq. (6)), since
cyclin E is abundant during the G1 phase (compare (Weinberg,
2007) Fig. 8.10 and (Gerard and Goldbeter, 2009) Fig. 2). CDK2–
cyclin E complex become degraded after the cell passes the G1
phase since CDK2 starts forming other complexes important for
the cell-cycle progression. Thus, the CDK2–cyclin E complex is
gradually diminished to zero after the G1 phase, which is repre-
sented in Eq. (6) as an appropriate decay term activated after the
G1 phase. The mathematical form of this decay term is not crucial
for our model as long as it depletes CDK2–E before the cell
division.
During the S phase, the cell needs to double its DNA content,
which we denote by the DNA replication index P. Thus P will
increase from 1 (the initial DNA contents) to 2 (the original DNA
and its copy) with a constant increase rate rp (Eq. (7)). This approach
reﬂects the dynamics of DNA replication, which occurs simulta-
neously at multiple locations of replication origins (Alberts et al.,
2008), and, as the replication process is being completed, the
number of active replication origins gradually reduces (Brummer
et al., 2010). Since the cell DNA is constantly exposed to chemical
products of various metabolic reactions that can cause DNA damage
((Weinberg 2007) reports as many as 10,000 genome modiﬁcations
in a single cell each day, that are removed by a highly effective DNA
repair system), we introduce a variable Q as a DNA damage index
that represents the cumulative effect of DNA damage and repair. Its
dynamics (Eq. (8)) depend on the cell cycle phase and, in the S
phase, on the stage of DNA replication. To consider this, we ﬁrst
decompose P into Pc, which represents the already duplicated DNA
and Po, which is the part of the DNA to be duplicated (Pc is equal to
zero during the G1 phase). The rates of DNA damage in Po and Pc are
denoted by rbd and rcd, respectively. We assume that rcd is higher
because, ﬁrst, if the region to be duplicated is already damaged then
the resultant copies also preserve or inherit this damage; second,
DNA replication is a stressful process that causes additional damage
to DNA (Burhans and Weinberger, 2007). We include three cate-
gories of DNA repair mechanisms in the model. The phase-
independent mechanisms, such as base excision repair and nucleo-
tide excision repair, take place throughout the cell cycle and are
represented by background repair rate rbr. The two phase-speciﬁc
mechanisms are nonhomologous end-joining, which is more active
in the G1 phase (repair rate rn), and HR, which is more pronounced
in the S and G2 phases (repair rate rh). We capture this phase
speciﬁcity in the model by applying suppression multiplier ksp and
cell cycle speciﬁcity function CST (where T denotes the cell cycle
phase, Eq. (10)) to rh or rn, depending on the current cell cycle
phase. To implement the stimulus from CDK1 to HR, we multiply
the HR rate by the amount of uninhibited CDK1. Non-
phosphorylated CDK1 (i.e., NCDK1–NCDK1y) turns into phosphorylated
CDK1 (NCDK1y) and the rate of change in phosphorylated CDK1
(NCDK1y) is proportional to the DNA damage index and the amount
of WEE1 (Kreahling et al., 2012; Branzei and Foiani, 2008), with
proportionality constant rCDK1y. The phosphorylated CDK1 is
Table 3
Model equations including cell cycle control Eqs. (1–11) and cell growth and
migration Eqs. (11–15).
dNCDK1
dt
¼ rCDK1ð1NCDK1Þ (1)
dNCDK2
dt
¼ rCDK2ð1NCDK2Þ (2)
dNWEE1
dt
¼ rWEE1ð1NWEE1Þ (3)
dNCDK1i
dt
¼ rCDK1iðNCDK1NCDK1iÞ (4)
dNCDK2i
dt
¼ rCDK2iðNCDK2NCDK2iÞ (5)
dNCDK2E
dt
¼ rCDK2Eð1CSG1ÞðNCDK2NCDK2iÞð1NCDK2EÞCSG1 UDecay (6)
dP
dt
¼ ð1CSSÞrpð2PÞ (7)
dQ
dt
¼ rbdPoþrcdCSG2Pc  ðrbrþrnð1 kspCSG1Þ
þrhð1 kspð1 CSG1ÞÞðNCDK1  NCDK1iÞÞQ ;where P ¼ PoþPc and Po ¼ 2 P
(8)
dNCDK1y
dt
¼ rCDK1yð1CSSÞQ UNWEE1ðNCDK1NCDK1yÞð1CSG2ÞdCDK1yNCDK1y (9)
CST ¼
0 in phase T; T¼G1; S; or G2
1 otherwise

(10)
da
dt
¼ rað
ﬃﬃﬃ
2
p
a0aÞ: (11)
f ij ¼
kðaiþajdijÞðxixjÞ if aiþaj4dij
0 if aiþajrdij
(
(12)
Ftotali ¼ ∑
ja i
f ij (13)
dxi
dt
¼ Fi
η (14)
Fmi ¼ b v
!
; v! is a random vector with j v!jr1: (15)
Table 2
Model variables.
Symbol Name
a Cell radius
P (¼PoþPc) DNA replication index
Q DNA damage index
NCDK1 Amount of CDK1
NCDK1y Amount of CDK1 with phosphorylation at Tyr 15
NCDK1i Amount of inhibited CDK1 (no contribution of DNA repair)
NCDK2 Amount of CDK2
NCDK2i Amount of inhibited CDK2 (no contribution to CDK2E synthesis)
NWEE1 Amount of WEE1
NCDK2E Amount of CDK2 and cyclin E complex
Table 4
Model parameters.
Symbol Name Value
a0 Typical cell size 5 μm
ra Cell radius growth rate (default) 0.19 μm/s
rp DNA replication rate 0.44 h1
rbd DNA damage rate (background) 0.01 h1
rcd DNA damage rate (copied part in S phase) 0.015 h1
rbr DNA repair rate (background) 0.3 h1
rn DNA repair rate (non-homologous end joining) 0.1 h1
rh DNA repair rate (homologous recombination) 0.4 h1
ks DNA repair suppress constant 0.1
rCDK1 CDK1 production rate 0.48 h1
rCDK1i CDK1 inhibition rate 0.045 h1
rCDK2 CDK2 production rate 0.48 h1
rCDK2i CDK2 inhibition rate 0.075 h1
rWEE1 WEE1 production rate 0.48 h1
rCDK1y CDK1y synthesis rate 2.4 h1
rCDK2E CDK2E synthesis rate 0.48 h1
dCDK1y CDK1y degradation rate in G2 phase 1 h1
ath Threshold for a in G1 phase 0.9521/2 a0
NthCDK2E Threshold for CDK2E in G1 phase 0.99
NthCDK1y Threshold for CDK1y in G2 phase 0.1
Qth Threshold for Q in M phase 0.02
k Repulsive spring constant 5 [k]
η Linear drag coefﬁcient 1 h  [k]
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degraded during the G2 phase, when DNA damage rapidly
decreases. We indicate this occurrence in Eq. (9) by using cell cycle
speciﬁcity function CSG2 and degradation rate dCDK1y.
In addition to the changes in the amount of intracellular
proteins, cell size increases during the cell cycle; such increase
plays a crucial role in enabling passage through the cell cycle
checkpoint and in regulating the cell cycle. The increase of cell size
follows Eq. (11) when no physical interactions occur between cells.
However, given that we are interested in studying the effects of
physical constraints on cell cycle progression, additional laws and
equations are necessary to capture cell–cell interactions and volume
exclusivity. These are described in detail in the next section.
Progression from one phase of the cell cycle to the next is
regulated by a series of checkpoints that are implemented using
the threshold values of certain variables for each speciﬁc phase
(Fig. 1). They have been chosen such that the duration of each cell
cycle phase is within the durations of the G1, S, and G2/M phases
reported for many mammalian cells (Alberts et al., 2008;
Weinberg, 2007; Tyson et al., 2012; Singhania et al., 2011). The
G1 phase is completed when cell size a and the amount of CDK2–
cyclin E (CDK2–E) complexes are higher than the prescribed
threshold values. Both thresholds and the rate constants in the
related equations are chosen, so that the duration of the G1 phase
is 12 h under the absence of both CDK2 inhibition and space
competition among cells. Under CDK2 inhibition, however, the
amount of CDK2–E increases more slowly, thereby prolonging the
duration of the G1 phase. If cell size remains below the threshold
because of spatial limitations, a cell may be prevented from
passing the G1 checkpoint. Either of these cases may lead to an
indeﬁnite duration of the G1 phase (called G1 arrest). The S phase
takes about 10 h and ends when cell DNA is doubled. We model
this phenomenon by choosing a threshold value of two for DNA
replication index P and an appropriate DNA replication rate.
The G2/M checkpoint is controlled by two threshold values
(Fig. 1) that should be reached in sequence. A cell will remain in
the G2 phase until the amount of phosphorylated CDK1 reaches a
level smaller than the prescribed threshold. This period is used for
repairing damaged DNA; such repair, in turn, reduces the amount
of phosphorylated CDK1. Once the ﬁrst threshold is reached, the
cell DNA damage index is immediately probed, and if this index is
below the threshold, the mother cell will divide. If the DNA
damage index is too high, a cell will undergo arrest in the G2/M
phase. When no inhibitors are present and the cell can successfully
divide, the span of the G2/M phase, typically 2 h, is determined by
the amount of phosphorylated CDK1 at the entrance to this phase.
When CDK1 is inhibited from stimulating HR, however, the DNA
damage index may remain at a level too high to enable successful
passage through the second G2/M threshold. Moreover, if WEE1 is
inhibited or its production is suppressed, the cell may enter the G2
phase with a diminished phosphorylated CDK1 that will result in
shorter time for DNA repair. During cell division, all proteins are
split equally between two daughter cells, except for CDK2–E,
which has already been diminished such that its amount in each
daughter cell is zero. Cell age is also reset to zero upon cell
division. Certain tumor cells and embryonic cells may have much
shorter doubling times, and we show in Section 4 how our model
can be tuned to match the doubling time for a particular cell line.
When enough space is available for cells to grow and when
neither CDKs is inhibited, all intracellular proteins show cyclic
behavior in every cell cycle, and all cells divide at about 24 h of
age. The evolution of the selected model variables over four
consecutive cell cycles is shown in Fig. 2. CDK2–E increases
steadily and reaches the threshold level in G1 phase (red) and
starts decay as soon as the cell enters the S phase (green). The
majority of cell growth (a) is completed in the G1 phase because
reaching a certain cell size is one of the conditions for passing the
G1 checkpoint; however, a slight increase in cell size may occur
during the other phases. P stays constant during the G1 phase and
doubles in the S phase (green) in order to pass the S checkpoint.
The main condition for cell division is the reduction of a cell's Q
index to a level below the threshold value before the cell enters
the M phase. The Q level is low after cell division and increases
slightly in the G1 phase, but quickly stabilizes because, in this
phase, P is constant but NCDK1 doubles. Q increases again in the S
phase, in which DNA is duplicated and damaged with higher rates
(rbd and rcd). During the G2 phase, Q rapidly decreases (blue) and
reaches its threshold, but continues to decline because the dura-
tion of the G2 phase depends on whether the phosphorylated
CDK1 falls below its threshold value. NCDK1y steadily rises during
the S phase with increasing level of Q; in the G2 phase, NCDK1y
rapidly decreases with Q and due to its own degradation. Both Q
and NCDK1y fall below their thresholds, and the G2/M phase ends
da
dt
= ra ( 2a0 a).
dQ
dt
= rbdP (rbr + rn + kspNCDK1rh )Q
da
dt
= ra ( 2a0 a).
dNCDK1
dt
= rCDK1(1 NCDK1)
dNCDK 2
dt
= rCDK 2 (1 NCDK 2 )
dNWEE1
dt
= rWEE1(1 NWEE1)
dNCDK1y
dt
= rcdk1yQ NWEE1(NCDK1 NCDK1y )
dP
dt
= rp(2 P)
dQ
dt
= rbdPo + rcdPc (rbr + ksprn + NCDK1rh )Q
dNCDK1y
dt
= rcdk1yQ NWEE1(NCDK1 NCDK1y ) dcdk1yNCDK1y
dQ
dt
= 0 rbdP (rbr + ksprn + NCDK1rh )Q
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M. Kim et al. / Journal of Theoretical Biology 352 (2014) 31–50 35
with cell division. The CDK1, CDK2, and WEE1 almost reach their
saturation levels during the G1 phase (red) and then change only
minimally during the rest of the cell cycle. The four discontinuity
points in the graphs in Fig. 2 represent the times of cell division.
2.2. Cell growth and migration
All cells, regardless of whether they are cultured in vitro or
grown in vivo, inevitably interact with neighboring cells and with
the environment. We recognize the importance of such spatial
interactions and introduce repulsive forces between nearby
cells as a mechanism for maintaining cell volume exclusivity.
This mechanism prevents cell overlap during growth and migra-
tion. Among the cell physical properties included in our model are
cell position, cell radius, repulsive forces between neighboring
cells (identiﬁed by the nearest neighbor search), orientation of cell
division, and direction and speed of cell migration. Fig. 3A shows a
small cluster of cells, together with the identiﬁed neighborhood
relationship and selected physical properties.
The cell size growth equation (Eq. (11)) describes a linear
increase in cell radius at a constant rate ra with an imposed
maximum cell size. We intend to model the in vitro cell culture,
wherein cells are conﬁned to a predetermined domain (such as a
Petri dish) and compete for space to grow while interacting with
one another. Given that cell–cell overlap is inevitable when Eq.
(11) is applied to each cell independently, introducing additional
mechanisms is necessary to resolve potential issues in cell volume
exclusivity. First, to accommodate two nonoverlapping daughter
cells within the space left by the mother cell just after its division,
we increase cell size during a mother cell's lifespan from a0/21/2
(when the cell is born) to 21/2a0 (just before cytokinesis), where
the cell reference radius is denoted by a0. Moreover, a straightfor-
ward numerical implementation of Eq. (11) for each individual cell
(ai¼a(tþΔt)), without consideration of the presence of its neigh-
bors, may cause tiny overlaps between the cells (i.e., aiþaj4dij), as
depicted in Fig. 3A. In such a case, we deploy an algorithm that
restores volume exclusivity for each cell (depicted in Fig. 3B and
summarized in Fig. 4) as follows: (i) the nearest neighbor search is
executed to determine cells with mutually infringed boundaries by
comparing the distance dij between two cell centers and the sum
of their corresponding radii. (ii) When a breach occurs, the
repulsive forces are applied to eliminate or reduce the infringed
volume. These forces are modeled using the linear elasticity
formula (Eq. (12)). When a cell has multiple overlaps, more than
one repulsive force may arise in different directions (including
opposite directions), and cell relocation (Eq. (14)) follows the total
repulsive force (i.e., Fi¼Fitotal). (iii) In many cases, this is sufﬁcient
to resolve volume exclusivity issues (aiﬁnal¼ai in Fig. 4(iii)). In some
cases, however, a particular cell continues to exhibit overlaps,
which may happen when the cell has more than one overlapping
neighbor. In such a situation, we ﬁrst examine whether we can
move the cell in a direction that reduces overlaps. The absence of
this direction is referred to as a surrounded case. (iv) If the cell is
dij aj
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xj
fij
fji
I
II
III
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V
Fig. 3. Model physical features. (A) Each individual cell is characterized by its position xi, and a radius ai. dij denotes the physical distance between cells xi and xj. When cells
overlap the repulsive forces fij (arrows) are exerted to restore volume exclusivity. (B) Diagrams (I)–(V) illustrate the algorithm restoring volume exclusivity between four
overlapping cells: the consecutive diagrams show how cell sizes evolve in one time step to ensure cell growth and volume exclusivity. The depicted overlapped sizes are
greatly exaggerated for visual purposes. The initial cell conﬁguration is shown in (I). When all cell sizes increase, following Eq. (11), the cells overlap and repulsive forces
between them are activated (II). Arrows with matching colors indicate pairs of repulsive forces that will result in cell relocation along the corresponding force direction; note,
that the middle cells experience three repulsive forces, and thus will be moved along the averaged direction—in the presented case this relocation is minimal. As a result, the
overlapping sizes have been reduced but not eliminated (III). The middle cell is surrounded; therefore, following step (iv) of the algorithm, its size needs to be reduced (IV).
The dashed circle in (IV) indicates cell size before reduction. The three other cells are not surrounded, thus according to step (ii') of the algorithm, they will be pushed along
the acting repulsive forces, away from the middle cell, without reducing their sizes (V). The dashed circles in (V) indicate previous locations of cells. The procedure described
in diagrams (I)–(V) represents one time step in our simulation.
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Fig. 2. Evolution of the cell cycle regulation variables in the case of no spatial
interactions between the cells and without cell cycle inhibitors. Dashed lines
indicate the threshold levels and colors show the cell cycle phases: G1 (red), S
(green), and G2/M (blue). Governing equations are listed in Fig. 1, and parameter
values are: rCDK1¼0.48 h1; rCDK2¼0.48 h1; rWEE1¼0.48 h1, rCDK2E¼0.48 h1;
rbd¼0.01 h1; rcd¼0.015 h1; rbr¼0.3 h1; rn¼0.1 h1; rh¼0.4 h1; ks¼0.1;
rCDK1y¼3.84 h1; dCDK1y¼1.08 h1; ra¼0.19 μm/h; rp¼0.44 h1; ath¼0.9521/
2 a0; NthCDK2E¼0.99; NthCDK1y¼0.1; and Qth¼0.02. All inhibition parameters from
Table 4 are set to zero here, and the cell cycle speciﬁcity function CST values are
explicitly assigned in Fig. 1. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)
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surrounded, we inspect all overlapping pairs and calculate their
weighed reduced radii aij, and take the minimum over all over-
lapping pairs as the ﬁnal radius (aiﬁnal in Fig. 4(iv)). This approach
eliminates all overlaps. (ii') If the cell is not surrounded, we reduce
cell–cell overlaps by calculating the total repulsive force acting on
that cell and move it along the direction of the force. Step (ii')
should be repeated until either the cell is surrounded or all the
overlaps are resolved. The concept of the surrounded cell and step
(ii') are introduced to avoid compromising the growth rate of
outermost cells when cells form clusters. In this algorithm, the
calculated aiﬁnal is not smaller than the cell radius in the previous
time step.
When cells overlap, equal but opposite repulsive forces are
exchanged between two overlapping cells. Force magnitude is
proportional to breached distance, with proportionality con-
stant k (Eq. (12)). If a cell (with index i) overlaps with multiple
neighbors, the total repulsive force exerted on it is calculated as
in Eq. (13), where j runs over the index set Ni of all the neighbors
of the ith cell. For the cell center, xi, its location is updated
following Eq. (14) using the total repulsive force from Eq. (13),
Fi¼Fitotal, and η, which denotes the linear drag coefﬁcient. In
numerical calculations with a discrete time step size Δt, the
moving distance is equal to FitotalΔt/η. We choose k, η, and Δt so
that they satisfy 2kΔt¼η, which is the condition imposed on
two growing daughter cells placed right next to each other. This
condition is necessary for the cells to increase their size
precisely in accordance with Eq. (11) without any overlap; such
an increase is achieved because the cells push each other and
grow in a precisely orchestrated manner. In this case, volume
exclusivity is realized at step (ii) of the algorithm shown in
Fig. 4, and no radius reduction (iv) is necessary. This choice of
parameters generally ensures stable numerical implementation
and warrants maximal volume exclusivity among all overlap-
ping cells after the repulsive forces in step (ii) are applied.
Fig. 3B shows an example of how to preserve volume exclu-
sivity while the neighboring cells are growing. Diagram (I) shows
the initial cell conﬁguration; diagrams (II)–(IV) show the inter-
mediate steps, and diagram (V) is the ﬁnal conﬁguration. The
overlapping areas are greatly exaggerated to demonstrate our
algorithm. Four neighboring cells (I) increase their sizes following
Eq. (11), which causes cell overlapping and activation of repul-
sive forces (II). Cell relocation, that follows the repulsive forces,
reduces but does not eliminate the overlaps (III). The middle
cell is surrounded; therefore, following step (iv) of the above
algorithm, the middle cell radius is reduced. Since the other
three cells are not surrounded, they are pushed away from the
middle cell following step (ii') of the algorithm without reducing
their sizes.
In our model, the cells can also actively move in a random
fashion. The voluntary movement of the ith cell is implemented by
applying a motility force, Fim, through Eq. (14) (i.e., Fi¼Fim). The
motility force Fim is a randomly chosen vector whose magnitude is
selected from a uniform distribution between zero and a pre-
deﬁned maximum (b in Eq. (15)) We set the magnitude of a typical
repulsive force m1 (m1¼2kΔa, where Δa is a typical radius
increment for Δt during the time at which a shows linear growth)
as the reference value. By setting 100m1 as the predeﬁned
maximum (b¼100m1), we qualitatively reproduce the behavior
of highly motile cells (as described in literature, e.g., in (Tyson
et al., 2012)). We refer to this as a “motility of 100” or m100.
At every time step, the motility force is assigned to each cell and
the cells move in accordance with the resultant velocity deter-
mined by Eq. (14). However, when this velocity is applied with the
previously chosen time step Δt, it may generate a large relocation
distance and signiﬁcant overlaps with nearby cells. When the
repulsive forces are reapplied in order to prevent cell overlap they
may become a source of numerical instability. Therefore, we
separate voluntary movements from relocation during cell growth
and use fractionated time steps to prevent such instabilities. That
is, once cell size and location are settled by the algorithm in Fig. 4,
the forces for voluntary movements are generated and time step
Δt is divided into a predeﬁned number of smaller time steps with
empirically chosen fractions (the fractionated time step). The cell
locations are then iteratively updated through the alternate
application of the motility and repulsive forces (with the fractio-
nated time step and Δt, respectively) to account for both cell
movement and cell overlap prevention.
To illustrate the different collective behaviors, we consider
three cell motility values (m1, m10, m100) and simulate growing
cell colonies starting with identical initial conditions shown in
the inset of Fig. 5A. Each simulation is carried out in a repre-
sentative 500500 μm2 domain that corresponds to a typical
image recording size of cell culture under a microscope (Tyson et
al., 2012). The population-doubling curves normalized by the
initial cell number and the snapshots taken at the end of each
simulation (at 168 h) are presented in Fig. 5A–D. As expected,
cells characterized by lower motility form tight clusters, while
high motility cells spread freely and cover more than half of the
available space (see Video 1). Most of the inner cells in the
clusters also grow more slowly because they detect space
limitations, and some stay in the G1 phase for more than 24 h
(denoted in magenta in Fig. 5B–D, 38% for m1, 26% for m10, and
negligible for m100). Also, the total ﬁnal populations for all three
cases are considerably different: m100 cell population is almost
twice as big as the m1 population.
To inspect in detail the cell cycle progression on an individual-
cell level, we traced the same cell in each of the three simulations,
and reported its size in Fig. 5E–G. In all three cases cell size growth
is identical during the ﬁrst three cell cycles (i.e., until about 72 h),
but the cycles beyond this period exhibit substantial differences.
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Atm1 (Fig. 5E), the cell growth during the fourth cell cycle shows a
signiﬁcant slowdown because the cell is surrounded by the
neighboring cells. However, no signiﬁcant deviation from one cell
cycle to another is observed at m100 (Fig. 5G), and the evolution of
cell size occurs strictly in accordance with Eq. (11). Similar trend
can be noticed at the population level (Fig. 5H–J). The observed
oscillations in cell cycle phase distribution occur because (i) the
cells' doubling times are assumed identical when no external
limitations exist; (ii) two daughter cells are born simultaneously
and are thus synchronized unless external inﬂuence is present;
(iii) each cell in the M phase (blue) gives birth to two cells in the
G1 phase (red). Thus, at m100, oscillations are present throughout
the entire simulation since no space limitation occurs until
conﬂuence is reached. At lower cell motility, the oscillations
disappear after several cell cycles because cell synchronization
is broken as the growth rate of cell size slows down for the
cells located inside the clusters: at around 80 h (m1) and 110 h
(m10). This very closely corresponds to the times at which the
graphs in Fig. 5E and F deviate from the initial cell size growth
dynamics.
3. Results
To investigate the effects of cell cycle inhibitors on cell
population growth, we consider both intrinsic and extrinsic
factors. These include the dynamics of intracellular factors that
regulate the duration of each phase of the cell cycle in every
individual cell, physical interactions between neighboring cells,
and cell competition for space. In the previous section, we also
showed that motility, as a property of each individual cell,
inﬂuences the spatial organization of cell colonies at the popula-
tion level. Thus, we want to examine whether the efﬁcacy of cell
cycle inhibitors is altered by emerging group traits. First, we
present a control case in which no cell cycle inhibitors are used,
the cells are quite motile, and they interact with one another.
Initiating the simulation with a small number of cells enables us to
observe the long-term evolution of growing cell populations until
spatial conﬂuence is reached. Second, we examine the effects of
CDK1 and CDK2 inhibitors (separately and in combination) in
comparison with those of the control. We again choose high
cell motility to distinguish the effects of growth inhibition due to
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cell–cell interactions from those of the cell cycle inhibitors. Finally,
we test the combined effects of the cell cycle inhibitors and cell–
cell physical interactions on cell population growth by integrating
various cell motilities and different cell cycle inhibitors.
3.1. Cell colony growth without cell cycle inhibitors
The simulation for the control case is initiated with 50 cells,
which constitute about 2.5% of the maximum population capacity
of the chosen domain size (500500 μm2). The cell locations
within the domain are randomly assigned. The age of each cell is
drawn from a uniform distribution between 0 and 24 h, which
determines the values of all cell cycle-related variables (a, NCDK1,
NCDK2, NWEE1, NCDK2E, NCDK1y, Q, and P) in accordance with the
graphs in Fig. 2. The chosen initial cell age also speciﬁes the
current phase of the cell cycle. Given the predeﬁned durations of
each cell cycle phase (12:10:2 h for G1, S, and G2/M, respectively)
and the random selection of cell ages, the cell population ratios of
the G1, S, and G2/M phases are expected to be roughly 50%:42%:8%
at the beginning of the simulation (such initial population ratios
are frequently observed in laboratory experiments (Singhania
et al., 2011; Cai et al., 2006; Chaudhry 2007), but we show in
Section 4 how our model can be tuned to other cell cycle phase
distributions). The simulation is carried out over 144 h until the
growing cell colony reaches 94% of conﬂuence. The population-
doubling curve normalized by the initial number of cells in the
log scale (diamonds) is shown in Fig. 6. The straight solid line
indicates the exponential population growth with a rate of (ln 2)/
24 per hour. The simulated population growth strictly occurs along
this line for about 110 h. Subsequently, it begins to plateau because
cell competition for space becomes a limiting factor. The four inset
ﬁgures show the simulation snapshots taken at 60, 84, 108, and
132 h, as well as the corresponding cell age distributions. We
assume that nutrients are abundant, and because the cells are
highly motile, there is enough space for all the cells to grow in
strict accordance with the graphs in Fig. 2. With time, however,
the cells start competing for space, and population growth slows
down because some cells do not satisfy the required G1 check-
point size (a) condition within the intended 12 h of G1 duration.
As the available space is diminished, therefore, an increasing
number of cells become trapped in the G1 phase (the G1-
arrested red cells dominate in the 132-hour snapshot); some of
these cells have spent more than 24 h in this phase (indicated in
magenta in Fig. 6, the 132-hour snapshot).
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The four age distributions in Fig. 6 conﬁrm this trend. In the
ﬁrst two snapshots, the phase-wise age distributions are well
separated and no cell is older than 25 h, indicating that all the cells
progress through the cell cycle without delay. At 108 h, a small
population of cells still in the G1 phase (red) but older than 12 h
begin to emerge (less than 1% of the total 625 cells in the G1
phase), implying that these cells cannot transition from the G1 to
the S phase in a timely manner. At 132 h, a large population of cells
remain in the G1 phase for more than 12 h (52% of the total 1576
cells in the G1 phase) with a widely spread age distribution
(0–32 h). This distribution is nearly threefold that seen in the
typical G1 phase duration conﬁrming the red cell domination
observed in the 132-hour snapshot in Fig. 6.
To look more closely into the effects of spatial competition, we
consider the relationship between cell size (a) and cell age
(Fig. 7A–C) at three different time points. The top solid curve in
each graph in the left column of Fig. 7A–C is the plot of the analytic
solution of Eq. (11). This plot dictates the expected increase in cell
size over time when no spatial limitations exist (the subsequent
lower lines are progressively decreasing percentile curves in 5%
decrements). Each circle represents an individual cell in the
culture, indicating its actual age (x-axis) and radius (y-axis). The
graphs in the right column of the ﬁgure show the histograms of
growth shortage, which is deﬁned as the ratio of the difference
between the expected and actual sizes normalized by the expected
size. The data at 84 h (Fig. 7A) show that all the cells exhibit size
growth in close accordance with the top growth chart (the analytic
solution of Eq. (11)), and that growth shortage is very low (more
than 98% of cells stay within 99.5% of the expected size). As the
population continues to increase over time, the competition for
space becomes signiﬁcant. At 108 h (Fig. 7B), several data points
diverge from the analytic solution graph, and the corresponding
histogram shows some cells with a growth shortage higher than
5%. However, no cell grows behind the expected size by more than
8%. The graph at 132 h (Fig. 7C) shows a considerably different
situation. The cell size versus age data signiﬁcantly deviate from
the analytic solution, and the maximum growth shortage reaches
35%, with more than the half of the cells showing the growth
shortage of 10% or higher.
Fig. 7D illustrates the evolution of the cell cycle phase distribu-
tion recorded every hour over 144 h. Throughout the entire
simulation, the G2/M phase ratio remains small (1–15%). The
characteristic G1-phase oscillations, visible for about 100 h, recon-
ﬁrm that most of the cells freely grow (and further divide). The
change in the G1 phase distribution pattern that occurs at around
120 h and the subsequent G1 phase domination are also consistent
with the plateau in the population-doubling curve in Fig. 6. These
phenomena are due to the space limitations that arise as the
computational culture becomes highly conﬂuent. At the end of this
simulation, the G1-phase ratio reaches 92%, reafﬁrming G1 phase
cell arrest.
3.2. Effects of CDK1 and CDK2 inhibitors on cell colony growth
Here, we present the results of incorporating the CDK1 and
CDK2 inhibitors to the model. We assume that the inhibitors act on
all the cells during the entire simulation, i.e., their effects are
temporally and spatially uniform. This assumption is consistent
with the clonogenic assay setup, where the medium in which the
cells are grown is periodically changed to keep the nutrients and
the therapeutic agent uniformly dissolved and available to all the
cells in the culture. We also assume that the cells in these
simulations are highly motile (m100) to distinguish between the
effects of cell cycle arrest due to CDK inhibition and those of
growth arrest due to spatial limitations. CDK2 inhibition is
expected to cause cell cycle arrest at the G1 phase because the
inhibited CDK2 slows down the CDK2–E buildup that is crucial to
enabling passage through the G1 checkpoint. CDK1 inhibition is
expected to cause cell arrest at the G2/M checkpoint because the
low amount of uninhibited CDK1 diminishes HR stimulation,
which in turn may result in cell entry into the M phase with a
DNA damage index that is too high to allow for cell reproduction.
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The effectiveness of the inhibitors as agents that suppress
population growth depends on the choice of inhibition parameters
(rCDK1i and rCDK2i). We examine the inhibition response curves of
each inhibitor by comparing the relative increment in population
size at 48 h (Fig. 8). The x-axis values represent the inhibition
ampliﬁcation factor; that is, the inhibition parameters of CDK1 and
CDK2 normalized by the chosen rCDK1i and rCDK2i values (in the
caption of Fig. 8), respectively. The y-axis represents the increment
in inhibited population with respect to the increment in control
population reached at 48 h. The initial cell conﬁguration and cell
age distribution are identical in all cases (with and without
inhibitors), and the inhibitors are applied at the beginning of the
simulation. Both curves show a decreasing logistic function that
levels off at the top and bottom of the graphs. Small values of
CDK1 and CDK2 inhibition parameters impose no noticeable
effects on cell population growth. With high inhibition para-
meters, cell population growth signiﬁcantly diminishes in both
cases, but the ﬁnal effects differ. With CDK1 inhibition, nearly
complete termination of population growth is observed. Conver-
sely, very strong CDK2 inhibition results in nonnegligible popula-
tion growth (about 20%). This result is attributed to the fact that
CDK2 inhibition cannot prevent cells from completing the ﬁrst cell
cycle and proliferating when cells at the beginning of simulations
have already passed the G1 phase, as is the case for about half of
the cells in our simulation. Therefore, at least 200 more cells
would have been born for 48 h. CDK1 inhibition can stop some of
the cells at the G2/M checkpoint and prevent them from complet-
ing the ﬁrst proliferation. This prevention accounts for the differ-
ences at the population increment levels for the large
ampliﬁcation factors in Fig. 8. We choose rCDK1i and rCDK2i around
the 50% level of population increase as our basic parameters (the
chosen values in the caption of Fig. 8), and use them to analyze the
effects of the CDK inhibitors.
Fig. 9 depicts the detailed analysis of four different simulations:
scenarios without any treatment (control), with CDK2 inhibition,
with CDK1 inhibition, and with the CDK1 and CDK2 combined
inhibition. All simulations start with 400 cells (about 20% of
conﬂuence) and identical initial cell conﬁgurations (inset of
Fig. 9A; the initial conditions are set by the method used in the
simulation in Fig. 6). All the inhibitors are effective at the start of the
simulation (from time 0). Inhibition parameters rCDK1i and rCDK2i are
chosen as presented in Fig. 8. The corresponding population growth
curves in log scale over 60 h for four cases (control, CDK2, CDK1, or
combined inhibition) are shown in Fig. 9A. The solid diagonal line
indicates the exponential population growth; during the entire
simulation, the control cells (black diamonds) exhibit an increase
that follows the exponential population growth line. With our
chosen parameters, the cell culture subjected to CDK2 inhibition
(red diamonds) shows 50.3% of the control population at the end of
the simulation; the cell culture subjected to CDK1 inhibition (blue
diamonds) reaches 42.2% of the control population. When the
inhibitors are applied in combination (green diamonds), the ﬁnal
population size amounts to only 35% of the control size.
Although the populations at the end of each simulation differ
considerably (Fig. 9A), all four cases show almost identical growth
for up to 22 h; that is, for a period corresponding roughly to one cell
cycle. This result is attributed to each inhibition taking place at a
certain point in the cell cycle (at the cell cycle checkpoint); the cells
need to reach this point for inhibition to have an effect. Further, the
inhibitors become more effective after the ﬁrst cell division is
completed and the daughter cells start a new cell cycle without
preaccumulated molecules. The CDK1-inhibited cell population
reaches a sudden plateau, whereas the CDK2-inhibited cell culture
continues to increase gradually, although at a much slower overall
speed. This difference is a consequence of the distinct dynamics of
each of the cell cycle checkpoints. The conditions in the G1
checkpoint are continuously tested for each cell in the G1 phase;
thus, a cell has multiple chances to pass this checkpoint. By contrast,
DNA damage is inspected only once in the M phase, preventing a
second opportunity for cells to pass the G2/M checkpoint. When the
inhibitors are combined, the population growth curve also reaches a
plateau. However, this combined effect is subadditively synergistic,
according to the fractional product concept (Webb, 1963), because
the remaining population at a ﬁnal time of 60 h, (i.e., 35%) is larger
than 21.2% (50.3% of 42.2%) of the control population. Since these
two inhibitor treatments in our simulation cause cell cycle arrest at
different phases, we do not expect super-additive synergy. The
CDK2 inhibition that holds cells in the G1 phase can deprive cells of
the opportunity to be arrested at the G2/M phase because of CDK1
inhibition. Nonetheless, given the fact that each inhibition allows
for the completion of one cell cycle, our observations indicate that
the maximal inhibition effect would be the termination of popula-
tion growth before it is doubled.
The population cell cycle distributions of each of the four cases
are shown in Fig. 9B–E. The patterns are very similar during the ﬁrst
12 h, conﬁrming that a lag time also exists in the cell cycle
distributions before the effects of the inhibitors become observable.
After this initial period, however, the population response is very
different. In the control group, the cell cycle distributions exhibit
two periodic ﬂuctuations, indicating that most of the cells complete
their cell cycles at least twice. This ﬁnding also conﬁrms the
exponential growth in cell population size shown in Fig. 9A. Never-
theless, close inspection of the graph of cell cycle phase distribution
(Fig. 9B) at the end of the simulation indicates the emergent effects
of spatial limitations (an increased population of G1 red cells),
suggesting that the population-doubling graph in Fig. 9A would
deviate from the diagonal line at a longer simulation. By contrast,
the three remaining simulations show no oscillations in cell cycle
distribution. The CDK2 and CDK1 inhibitor treatments result in G1
and G2/M arrests, respectively (Fig. 9C and D). Combining the
inhibitors causes a mixed effect: cell population is roughly halved
between the G1 and G2/M phases at 60 h (Fig. 9E). Over the ﬁnal
24 h, however, the observed trend is of a decreasing G1 population
and an increasing G2/M population because the chosen CDK2
inhibition parameter enables the cells to pass the G1 checkpoint
slowly and move on to the S and G2/M phases. Upon reaching the
G2/M phase, the cells are permanently arrested, thereby keeping
the population size constant. We expect the population ratio
G1:G2/M to stabilize at around 50:50 if the simulation is run for
an extended period. For the graphs in Fig. 9F–I, we choose two
particular cells (one of each set of graphs) that fail to complete two
full cell cycles. We then record the evolution of several speciﬁc
intracellular variables. Fig. 9F and G show three variables relevant to
CDK2 inhibition (NCDK2, NCDK2i, and NCDK2E), and Fig. 9H and I show
three variables relevant to CDK1 inhibition (NCDK1, NCDK1i, and Q).
The amount of inhibited CDK2 (NCDK2i, plus signs in Fig. 9F) reaches
more than 50% of the total CDK2 amount soon after the beginning
of the second cell cycle. This increase results in a slower progression
of NCDK2E synthesis (Fig. 9G). Thus, the cell reaches the threshold
level (horizontal line) in 38 h (it should take 12 h normally) and
transitions into the S phase. This result explains the lack of
oscillation in the population cell cycle distributions shown in
Fig. 9C. Conversely, even if both the total CDK1 and the inhibited
CDK1 (Fig. 9H) show dynamics similar to that of CDK2 (Fig. 9F)
during the second cycle, the progression through the cell cycle
reaches a phase that differs from that observed in CDK2 inhibition.
The high amount of inhibited CDK1 does not prevent cell progres-
sion from the G1 to the S phase and from the S to the M phase.
Nevertheless, because the level of DNA damage steadily increases to
a level higher than that achieved in the ﬁrst cycle over time (Fig. 9I),
the cells fail to reduce the damage below the threshold during the
DNA repair phase in the second cycle. This failure causes cell arrest
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in the G2/M phase (Fig. 9I). Fig. 9J–M show the ﬁnal snapshots from
each simulation, with the corresponding phase-wise age distribu-
tions. The control case (Fig. 9J) and the CDK2 inhibition case
(Fig. 9K) both show G1 phase (red) cell domination, but for different
reasons. For the control case, the G1 phase arrest of cells is caused
by spatial limitations, whereas for CDK2 inhibition case, such arrest
is caused by slow CDK2–E synthesis. These phenomena are initiated
at different times, as shown in the G1-phase age histograms. With
CDK2 inhibition, most of the cells in the G1 phase are considerably
older than those in the control case, indicating that the cells become
G1 arrested early in the simulation and remain arrested for a long
period. By contrast, the majority of the G1-phase cells in the control
case are young but more densely packed, preventing them from
progressing through their cell cycles. The complete G2/M phase
(blue) cell domination shown in Fig. 9L starts at 54 h (shown in
Fig. 9D). This result is attributed to the implementation of G2/M
arrest as a permanent cell arrest (not a prolonged process in a
phase) and the fact that our choice of CDK1 inhibition parameter is
high enough to allow only two cell divisions at most. Fig. 9M shows
the ﬁnal simulation snapshot (at 60 h) of the cell colony exposed to
the combined inhibitors. Almost half of the cells are in the G1 phase
(red), and the other half are in the G2/M phase (blue), with some
cells occasionally found in the S phase (green). Given that our
choice of parameter for CDK2 inhibition continues gradually to
enable cells to escape from the G1 phase, we can expect slowly
decreasing G1-phase cells. Nonetheless, because the G2/M phase-
arrest is permanent, the entire population does not increase,
as conﬁrmed by the plateau in the population-doubling curve
(Fig. 9A).
3.3. Inhibitor efﬁcacy depending on cell motility
Thus far, we have investigated CDK inhibition in conjunction
with high cell motility (m100) only. As shown in the cell growth and
migration section, low cell motility leads to local overcrowding that
inﬂuences cell cycle progression; our intention is to distinguish
interruptions of the cell cycle due to CDK inhibitors from the
overcrowding effects. In the previous sectionwe have demonstrated
that cell arrest at different cell cycle phases is not necessarily
synergistically super-additive, suggesting that the low cell motility
in our model can alter the effects of CDK1 or CDK2 inhibitors. To
explore this idea further, we compare the results of simulations in
which two different motilities (low m1 and high m100) are used in
conjunction with single and combined CDK inhibitors.
We aim to examine how the CDK inhibitors affect cells that
have already formed clusters (as shown in Fig. 5); thus, we start
our simulations with 50 cells and allow these to grow without
exposure to any inhibitors until the population reaches 400 cells.
The cells with motilities of m100 and m1 take 74 and 77 h,
respectively, to reach the population of 400 (Fig. 10B, middle
panels). This waiting time enables the m1 cells to form small but
tight clusters, and the m100 cells to spread across the computa-
tional domain. Such a scenario is typical for in vitro experiments
that are always preceded by a period at which cells are allowed to
attach and grow in fresh media. After this incubation time, the
action of a chosen inhibitor is initiated (red arrows along the
population-doubling curves in Fig. 10A, also in Fig. 11A and D), and
the simulation is run for additional 60 h. This extension enables
comparison with the results in the previous section, in which each
simulation is initiated with 400 cells and run for 60 h.
First, we investigate the effect of CDK1 inhibition (Fig. 10).
In both cases (m1 and m100), population size steadily increases for
about 20 h after the addition of the inhibitors. However, the
population growth of m1 is slower, indicating that not all cells
actively progress through their cell cycles and divide. Both
populations reach (different) plateaus at about the same time
(Fig. 10A), but a clear distinction is observed in spatial distributions
and phase structures, as shown in the ﬁnal simulation snapshots
(Fig. 10B, bottom two panels) and in the cell cycle distribution
(insets in Fig. 10A). While the m100 cells are all arrested in the
G2/M phase (similar to that depicted in Fig. 9L), the m1 cells
also exist in both the G1 and S phases. These cells are located
inside the clusters, indicating that they are still in the G1 and S
phases because of spatial limitations; they do not progress
through their cell cycles and avoid the cell cycle arrest effect of
CDK1 inhibition. Only the outer cells are arrested at the G2/M
phase by CDK1 inhibition. The last 60 h in the cell cycle distribu-
tion graphs in the insets of Fig. 10A show patterns similar to those
in Fig. 9D and E, where the CDK1 and combined inhibitor
treatments are applied to the m100 cells. The graphs in Fig. 9D
and the upper left inset of Fig. 10A are similar because of the way
both computational experiments are designed. The similarities in
Fig. 9E and the lower right inset of Fig. 10A indicate that the low
cell motility plays a role that is analogous to that of CDK2
inhibition through the conﬁnement of cells in the G1 phase arrest.
When the simulations are run without incubation time, that is,
when the inhibitors are applied before the cells form clusters, no
noticeable difference in inhibition efﬁcacy was observed between
the results obtained after 60 h of both simulations (Fig. 10C). In
these cases, almost all cells, regardless of their motility, become
arrested in the G2/M phase because the cells can undergo only a
limited number of cell divisions and fail to form clusters large
enough to contain an inner region where cells are constrained by
space limitations.
Next, we investigate the effects of the CDK2 and combined
inhibitor treatments on the cells of both motilities (Fig. 11). All the
simulations are conducted in a manner similar to the CDK1
inhibition case. For m100, the results observed during the ﬁnal
60 h in Fig. 11 are comparable to those shown in Fig. 9, both in
terms of the shape of the population growth curves (compare
Fig. 9A, 11A, and 11D), and the evolution of cell cycle phase
distributions (compare Figs. 9C and 11B, and Figs. 9E and 11E).
In contrast to the results simulated in the sole CDK1 inhibition, the
results of the CDK2 and combined inhibitor treatments are very
similar regardless of cell motility; the population growth in
Fig. 11A and D; the cell cycle distributions in Fig. 11B and C, and
in Fig. 11E and F. For CDK2 inhibition, this result may be attributed
to the fact that both CDK2 inhibition and low cell motility cause
cell G1 phase arrest. At the end of both simulations (Fig. 11B
and C), most of the cells are in the G1 phase. For m100, this result is
attributed to CDK2 inhibition, but for m1, the effect stems from the
combined effect of CDK2 inhibition (for the inner and outer cells)
and spatial limitations due to low motility (for the cells in the
clusters). Thus, the ﬁnal population of m1 is slightly smaller than
that of m100. For the combined inhibitors, the ﬁnal populations in
both cases contain cells that are present in all the cell cycle phases.
The 137-hour snapshot of m1 (Fig. 11D, bottom) shows that the
cells in the G1 phase (red) are located on the edges of cell clusters,
in contrast to the same motility and time snapshot in Fig. 10B.
These cells are arrested in the G1 phase because of CDK2 inhibi-
tion. The inner cells in the G1 phase (red) are affected by both
CDK2 inhibition and low motility. The G2/M-arrested (blue) cell
population is a result of CDK1 inhibition, and no blue cells are
found in the inner regions of the clusters. Again, the m100 cells
(Fig. 11D, top snapshot) are scattered throughout the domain and
arrested in either the G1 or the G2/M phase.
4. Discussion
In this paper, we presented a newly developed model that
couples the dynamics of intracellular factors regulating the cell
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cycle with the mechanical interactions that occur during cell
growth, division, and movement, taking particular care to assure
cell volume exclusivity. We built the model to capture the essence
of the CDK1 and CDK2 inhibition processes. In the construction,
we used cell cycle checkpoints to model cell cycle progression and
phase-speciﬁc cell arrest. We also incorporated physical
constraints, such as repulsion forces, contact inhibition, and cell
overcrowding to reproduce a typical setup of clonogenic assay
experiments. Thus, this spatially explicit hybrid model of discrete
cells equipped with individually controlled cell cycles enables the
analysis of emerging behaviors at the cell population level, while
allowing for modiﬁcation of the properties of each cell independently.
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Our model differs signiﬁcantly from typical models of cell cycle
control that are compartmental, that is an entire cell population is
divided into several subgroups (compartments), each deﬁning a
different phase of the cell cycle. The progression through the cell
cycle is modeled by transferring a small portion of cells from one
phase to another following the predeﬁned transition rates that
may capture effects of particular drugs or cell line characteristics
(Eladdadi and Isaacson, 2011; Roe-Dale et al., 2012). These models
successfully reproduce experimental observations of the popula-
tion cell cycle distributions, but as individual cell cycles progress,
they miss certain detailed dynamic characteristics of cell cultures
that comprise heterogeneous cells. Within a compartment, cell
population is averaged, and the information on individual cell
cycle progress within a phase is coarse-grained. The individual cell
behavior, such as the extent to which the cell has progressed
through the phase, or the time necessary to complete passage
through a checkpoint and progression to the next phase, cannot be
reproduced by simply multiplying transition rates with population
size. One can overcome this downside by introducing more
compartments and time-delay terms in governing equations
(Simms et al., 2012), or by introducing a simultaneous time and
age dependency (Basse and Ubezio, 2007). As the number of
compartments increases, however, the compartmental model
converges to individual cell-based models, such as that described
in this paper. Therefore, the individual cell model can be con-
sidered the ultimate form of the compartmental model.
In contrast to models that disregard spatial aspects in relation
to cell population growth, in the discrete agent-based models the
basic model components representing the cells act as independent
but interacting agents. These models usually incorporate spatial
aspects, such as cell locations, colony shapes, or resource distribu-
tions. Depending on the geometric degree of freedom, modeling
styles can be divided into two classes: on-lattice and off-lattice
models. On-lattice agent-based models are variations of the
cellular automata models based on a square or hexagonal lattice
(Powathil et al., 2012, 2013; Anderson, 2005; Anderson et al.,
2009; Aubert et al., 2008; Enderling et al., 2010; Gerlee and
Nelander, 2012; Jiao and Torquato, 2011; Kam et al., 2012; Alber
and Kiskowski, 2001; Dubois et al., 2013) or Cellular Potts models,
in which each cell is composed of several lattice sides (Jiang et al.,
2005; Poplawski et al., 2009; Shirinifard et al., 2009; Turner et al.,
2004). These models adopt strict (lattice-based) rules regarding
cell location and possible movement directions, thus their geo-
metric setup is straightforward to program and relatively compu-
tationally inexpensive. However, Cellular Potts-type models can be
highly complex depending on how many lattice points an indivi-
dual cell can occupy. Conversely, off-lattice models have no
restrictions on cell location and direction of cell movement.
Among the off-lattice agent-based models of cell colony growth,
the cell-centered models are probably the most utilized model
frameworks (D'Antonio et al., 2013; Drasdo and Hohme, 2005;
Dunn et al., 2012; Galle et al., 2005; Macklin et al., 2012; Meineke
et al., 2001; Ramis-Conde et al., 2008; van Leeuwen et al., 2009;
Fletcher et al., 2012; Szabo et al., 2010), sometimes applied in
combination with a continuum description to represent densities
or populations of inactive cells, such as nonproliferating, quies-
cent, or necrotic cell regions (Kim and Othmer, 2013; Kim et al.,
2007). More complex models trace cell membrane points or cell–
cell boundary interface inputs, as in the vertex-based models
(Mirams et al., 2013; Osborne et al., 2010), Voronoi–Delaunay
cellular models (Beyer and Meyer-Hermann, 2007; Schaller and
Meyer-Hermann, 2005), and ﬂuid-based elastic cell models
(Anderson et al., 2009; Kam et al., 2012; Rejniak, 2007). The
subcellular element models (Sandersius and Newman, 2008;
Sandersius et al., 2011) explore internal cell complexity by includ-
ing not only the cell surface but also the intracellular components.
In these modeling frameworks, cell–cell interactions and cell–cell
neighborhood relationships are deﬁned in a more realistic manner,
however they require much more complex multistep-algorithms
for tracing all cells, determining the cell's immediate neighbors,
and assigning the axis of cell division to place new daughter cells.
Despite the fact that agent-based models are naturally suited to
equip each cell with individually regulated control mechanisms,
only limited information regarding cell cycle progression has been
incorporated in these frameworks (Fletcher et al., 2012; Schaller
and Meyer-Hermann, 2005; Alarcon et al., 2005). In two recent
papers adopting the cellular automata framework to model cell
colonies (Powathil et al., 2012; Powathil et al., 2013) the emerging
intracellular heterogeneity results from changes in cell cycle
phases in response to cell cycle speciﬁc chemotherapeutic agents
or to radiotherapy, respectively. This internal heterogeneity, in
turn, inﬂuences cell response to these anticancer treatments, and
may lead to cell cycle mediated drug resistance or to modiﬁed
radiation sensitivity. Cell cycle synchronization during radiother-
apy has been also investigated using the off-lattice agent based
model (Kempf et al., 2013).
The mathematical framework of our model is based on the
mechanistic model introduced by Meineke et al. (2001). However,
we extended this model by incorporating mechanisms of cell cycle
inhibition responses, and by imposing signiﬁcant constraints on
cell–cell interactions during cell growth and migration. In our
model the increment in size during cell growth is controlled by
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the available space to ensure cell volume exclusivity, and the cells
with multiple neighbors may grow slower than sparsely placed
cells. When cells are overcrowded their growth is suppressed until
the space is available. The growing or moving cells can push on
their neighbors and are, in turn, exposed to the counteracting forces
exerted by the nearby cells. The ﬁnal cell relocation is the result of
force balancing. These features enable the derivation of quantitative
results on both population and individual cell levels.
We investigated in this paper how individual cell responses to
combinations of CDK inhibitors affect the growth of an entire cancer
cell population. In particular, we were interested in inhibitors of
CDK1 and CDK2, which are known to regulate passage through the
G2/M and G1 checkpoints of the cell cycle, respectively. We exam-
ined more closely three cell cycle arrest mechanisms: (1) DNA
damage that is linked to CDK1 inhibition and causes G2/M arrest;
(2) CDK2–cyclin E complex formation that is associated with CDK2
inhibition and induces G1 arrest; and (3) cell growth dynamics and
physical cell–cell interactions that may lead to G1 arrest as a result of
cell competition for space and contact inhibition. We also looked into
the combined effects of these mechanisms. The ﬁrst twomechanisms
are related to a cell's intrinsic response to CDK1 and CDK2 inhibitors,
and the last one considers extrinsic factors that growing cells
encounter in either cell cultures or tissues. We simulated and
compared four different computational experiments: a control case
(without inhibitors), two cases in which one of the inhibitors was
applied (either CDK1 or CDK2), and a case in which the inhibitors
were simultaneously applied. In all the cases, the cells were assumed
highly motile to distinguish the intra- and intercellular aspects of cell
cycle arrest. We comprehensively analyzed all the computational
experiments in terms of population-doubling curves and population
cell cycle and age distributions, as well as provided snapshots and
videos of the dynamic simulations. These quantitative measurements
were chosen because they can also be collected from laboratory
experiments (i.e., counting of viable cells, ﬂow cytometry analysis,
and time-lapse microscopy movies). Our simulations show that
during the initial 12 h, the effects of the three inhibitor treatments
cannot be distinguished from one another and from the control case,
as indicated by the cell cycle distribution graphs; and during the ﬁrst
24 h, these effects cannot be distinguished by inspecting the
population-doubling curves or the conﬁgurations of growing cells
from the colony assay. These ﬁndings may provide insight into when
and how often data should be collected through laboratory experi-
ments to obtain comparable results or results that are distinguish-
able. We also showed that cell cycle inhibitors that cause cell arrest at
different cell cycle phases are not necessarily synergistically super-
additive.
We studied whether the spatial patterns formed by growing
cells affect the efﬁcacy of cell cycle inhibitors. We ﬁrst examined
three cases, in which cells of increasing motile abilities were not
exposed to inhibitors. We showed different emergent traits in
colony structures, such as the formation of tight cell clusters
versus uniform cell dispersal. These simulations reveal signiﬁcant
effects on cell cycle regulation. Different ﬁnal population sizes
with less motile cells produce the lowest number of offspring
because of the G1 phase cell arrest within cell clusters. The cell
cycle distribution dynamics show signiﬁcant differences between
the cases, with continuous oscillations in cell cycle distribution for
highly motile cells; the cell cycles of the inner (surrounded) cells
in the clusters are interrupted (G1 arrest) at low cell motility.
Finally, the formation of tight clusters (due to low cell motility)
alters the efﬁcacy of cell cycle inhibitors by acting as the G1 arrest
mechanism. As a result, a remarkable difference exists between
the outcomes produced by cells of high and low motilities when
they are exposed to CDK1 inhibitor. At high motility, all the cells
are arrested in the G2/M phase. However, the low motility cells are
arrested in the G1 and G2/M phases, and G1 arrest is attributed
exclusively to cell contact inhibition in the inner cells surrounded
by the G2/M-arrested cells.
The main reason for which the CDK1 efﬁcacy is affected by
tight cell cluster formation is slow overall dispersal of the cell
colony because the peripheral cells limit movement and growth
of the inner cells. We presented so far the results of our 2D
simulations. However, it is essential to extend our model to the 3D
space, because adding one spatial dimension increases the free-
dom in cell movement, In particular, the mean square displace-
ment of a random motility in 3D is 50% larger than that in 2D.
Similarly, sphere packing density in 3D is larger than in 2D; that
may be an important factor in determining cell overcrowding. In
order to examine whether CDK1 inhibitor efﬁcacy affected by cell
cluster formation is not a phenomenon limited to the 2D space, we
extended our model to the full three dimensions. In the extended
model cells are represented by spheres (that is, cell center location
and its radius). All algorithms for cell growth, migration and
determining the cell immediate neighbors are formulated identical
as in the 2D model but extended to 3D. Several snapshots from a
3D simulation are shown in Fig. 12 and conﬁrm the formation of
the G1-arrested core cluster and the G2/M-arrested cluster edge,
similarly as in the 2D case shown in Fig. 10. Here, the simulation is
run in the domain of size 500500500 μm3 and is started with
10 initial cells (Fig. 12A, 0 h). The CDK1 inhibition is turned on after
225 h where the whole cell population count is 3940 (Fig. 12A,
225 h). It is evident that after additional 60 h all outer cells in each
cluster are in the G2/M phase arrest (Fig. 12A, 285 h). In order to
show the inner cells, we use the cluster cross-sectional views. Four
such cross sections (at z coordinates 50, 70, 90, and 110 μm from
the bottom of the domain) are presented in Fig. 12B. Two cross
sections cutting roughly through the center of the cluster (z¼50
and 70 μm) show that all cells along the cluster edge are in the
G2/M phase, but the majority of cells inside the cluster are
arrested in the G1 phase with small number of cells in the S
phase. As the cross sections move up and toward the cluster
boundary (z¼90 and 110 μm) more cells are in the G2/M phase
indicating that they were able to pass through the G1 and S phases
and displayed the effect of CDK1 inhibition. Although the results in
Fig. 12 clearly show that this double-phase arrest in cell clusters
exposed to the CDK1 inhibitor is not solely 2D phenomenon, they
also suggest that 3D simulations require generation of larger
clusters (and thus both larger numbers of cells and longer times
of cluster growth) in order to observe cell separation into G1-
arrested core and G2/M-arrested cluster edge. Since adding one
spatial dimension enables cells to move around more easily and
avoid being surrounded by other cells, even the cells in the middle
of the cluster often ﬁnd space to grow or move, and thus it takes
more cells to create an environment where individual cells are
trapped.
We demonstrated that spatial cellular organization at the time
of drug administration is an important factor that inﬂuences the
effects of cell cycle inhibitors, even when all cells are uniformly
exposed to the drug, as in our model. Our ﬁndings may have
implications for in vivo tumor growth, because drugs are typically
applied after tumor masses have formed and have been detected.
We illustrate this point with the following hypothetical scenario.
If cell motility is low, the proliferating cell population will form
clusters, with inner cells arrested in the G1 phase given space
limitations. When these cells are exposed to the CDK1 inhibitor,
the outer cells are G2/M-arrested (similar to that shown in Figs. 10
and 12), and thus may incur high DNA damage. However, the inner
cells sustain less DNA damage because they are already arrested in
the G1 phase where the CDK1-stimulation requiring HR is not
pronounced. Now, if chemotherapeutic treatment is scheduled
weekly, the effects of CDK1 inhibition may be temporary and will
diminish between consecutive treatments. On top of that, if the
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G2/M-arrested cells die because of high DNA damage clearing the
nearby space, the previously trapped G1-arrested cells can resume
their growth and progress through their cell cycles, thereby
repopulating the tumor. A similar argument also applies to
combined inhibitors. Fig. 9 shows that when CDK1 and CDK2
inhibitors act in conjunction, the resultant cell population growth
proceeds at a slower pace than that observed in single inhibition
case; the ﬁnal population is the smallest among the three treat-
ments. The CDK1-inhibited population (in which all the cells are
arrested due to high DNA damage) poses less of a threat than does
the population grown under combined inhibition, even though the
remaining population shown in Fig. 9 is larger.
In order to increase practical and clinical importance of our
model, it needs to be calibrated with experimental data acquired
and measured by widely used laboratory techniques to ﬁt not only
various characteristics of particular cell lines of interest but also
pharmacodynamic features of certain drugs. The typical cell size
(parameter a0), cell motility (parameter m1–m100) and cell cycle
length can be extracted from time-lapse microscopy movies
(Sakaue-Sawano et al., 2008; Tyson et al., 2012; Georgescu et al.,
2012). In these experiments, sequences of images are taken to
show regions of the dish in which the cells are growing. By tracing
individual cells from one image to another one can record how cell
position, shape, and size are changing over time, and how often
the cells produce the offspring. Viable cell count is often mon-
itored to determine the population doubling curves (Tyson et al.,
2012; Cai et al., 2006), that can be used to validate or adjust our
results shown in Fig. 5A or Fig. 6. Additionally, the dynamic
changes in cell cycle phase distributions, which can be measured
from ﬂow cytometry cell sorting experiments (Bartkova et al.,
2005) or from microscopy images after FUCCI staining (Sakaue-
Sawano et al., 2008), can be compared with our dynamic simula-
tions. Results of these experiments can be reported as bar-graphs
with the ratios of cells being in the G1, S or G2/M phase,
respectively, which can be directly compared with our simulated
results shown in Fig. 5H–J or 7D. Experimental results, however,
rarely record high frequency data in contrast to our simulations
(Powathil et al., 2013; Singhania et al., 2011; Cai et al., 2006);
therefore, by using the computational model we are able to supply
the intermittent data points in the dynamics. Fig. 13A shows an
example of how the distributions of cell cycle phases under
the drug treatment can be used to calibrate our model. Here,
we consider a drug that inhibits both CDK1 and CDK2 but
with unknown inhibition strengths. Nine panels in Fig. 13A
show simulated results of the cell cycle phase distributions up to
60 h in 12-hour intervals using nine different combinations of
inhibition parameters. All other parameters that control each cell
cycle phase length, cell size growth rate, DNA replication rate, and
the threshold levels for checkpoints are identical for every con-
sidered simulation. Each of the nine panels display different
pattern of population cell cycle progression that depends on
how strong the inhibitions are, and which of the two inhibitions
is stronger. Hence, we can compare these simulated outcomes to
the experimental results showing cell cycle phase distributions
over time to pinpoint the right combination of model parameters
or to narrow down the possible region in the model parameter
space by eliminating unlikely combinations. The drug response
curves, which are typically used in the drug testing experiments
(Bai et al., 2012; Gray et al., 2012; Kreahling et al., 2013), can be used
to further calibrate our model. Fig. 13B displays dosage response
curves of ﬁve different hypothetical drugs which are represented by
ﬁve pairs of inhibition parameters (from Fig. 13A). Again, by
comparing these simulated outcomes to the drug response curves
determined experimentally, we can identify model parameters for
which the simulated results ﬁt the experimental ones.
The increased proliferative activity of cancer cells regulated by
CDKs provides opportunities for developing new therapies that
target CDKs with the reduced systemic toxicity that is typical of
conventional chemotherapeutic agents. Several CDK inhibitors have
already been developed and applied either in clinical trials or
advanced preclinical testing. The most promising are ﬂavopiridol,
seliciclib, and dinaciclib (Fu et al., 2011; Parry et al., 2010; Malumbres
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Fig. 12. CDK1 inhibition with the motility m1 in 3D. (A) Selected simulation snapshots in the domain of 500500500 μm3. The simulation starts with ten cells without
CDK1 inhibition. After waiting for 225 h, when clusters are big enough, the CDK1 inhibition is initiated. Sixty hours later a majority of visible cells are blue, indicating that
they are in G2/M phase. See Video 5 in the Supplementary material for the animated snapshots from the simulation. (B) Selected cross-sections from the rightmost panel in
(A) are shown to display the cluster inside. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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et al., 2008; Shapiro, 2006). However, no new therapies have been
approved for clinical use. Most of the CDK inhibitors being developed
have multiple targets. Whether selective inhibitors, called third-
generation CDK inhibitors, will be therapeutically superior to multi-
target CDK-inhibitor combinations remains unknown (Malumbres
et al., 2008; Shapiro, 2006). In this study, we regarded CDK1 and
CDK2 inhibition as two separate mechanisms coming from two
different inhibitors, enabling us to determine their individual activ-
ities and their combined effects on cell population behavior. This
approach can be easily extended to the study of multitarget CDK
inhibitors that are in trial, or used to propose new inhibitors that are
more effective. We presented our results as a minimalistic framework
that can be potentially extended to multiple CDK inhibitors or CDK
inhibitors combined with other types of drugs.
We intentionally simpliﬁed certain elements of our model to
reduce the number of model variables and parameters, but
appropriate model extensions are being developed. In the current
work, we did not explicitly include any of the numerous cyclin–
CDK complexes that are known to change dynamically in normal
proliferating cells. Instead, we focused only on CDKs as represen-
tative factors in cell cycle progression and in the passage of cell
cycle checkpoints (Gerard and Goldbeter, 2009; Tyson and Novak,
2008). We also concentrated entirely on cell cycle arrest at both
the G1 and G2/M checkpoints and did not introduce cell death to
the model. This decision was born of the fact that different cell
lines and different patients' tumors may be characterized by
distinct sensitivities to DNA damage that trigger cell death.
These cell line-speciﬁc characteristics should be part of model
calibration.
We focused most of our efforts on modeling the 2D in vitro
clonogenic assay. Such in vitro experiments are extensively con-
ducted in cancer biology research because they provide relatively
well-controlled environments in which to test hypotheses without
compelling researchers to contend with the overwhelming num-
ber of unknown or redundant factors usually encountered in
in vivo studies. With regard to controlled systems, in vitro cell
line experiments and mathematical modeling share these advan-
tages, making them a good combined approach. Quantitative
experimental measurements for model parameterization and
validation are the crucial building blocks of integrative mathema-
tical models. Meanwhile, the experimentally testable predictions
and hypotheses from mathematical models should be tested in
laboratories. Having this positive feedback loop between experi-
ments and simulations necessitates a mathematical model that is
extendable and ﬂexible, and at the same time, capable of produ-
cing results that are equivalent or comparable to experimental
ﬁndings. In this paper, we have shown that our model is versatile
and can produce results that are directly comparable to experi-
mental measurements, including life-like image series, such as
bright ﬁeld microscopy or time-lapse imaging; ﬂuorescent cell
labeling that indicates cell cycle phases FUCCI; population-
doubling curves acquired by counting viable cells over time; and
cell cycle distributions obtained from ﬂow cytometry analysis.
Other experimental measurements and data, such as Western
blots, microarrays, and image data also facilitate the parameter-
ization of models and the validation of computational results.
We showed that our computational model is readily extendable
to 3D experiments, such as multicellular spheroid cultures, or
tumors that grow in vivo in tissue-like structure. We assumed that
the CDK inhibitor-carrying drug is supplied uniformly to all cells,
but the model can incorporate various chemical spatial and
temporal gradients. Since we model individual cells, we can derive
quantitative results on both single-cell and population levels. We
can also visualize spatial traits, such as cell colony formation or
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Fig. 13. Simulated responses to various drug characteristics and dosage. (A) Population cell cycle distributions taken at 12-hour intervals between 0 and 60 h. Each panel
corresponds to cell population response to different sets of CDK1 and CDK2 inhibition parameters (representing hypothetical drugs). The center panel is the case referred to
as the combined CDK1–CDK2 inhibition in Fig. 9. (B) Dosage response curve following ﬁve different hypothetical drugs. The markers on the graphs represent size of cell
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location-dependent cell cycle speciﬁcities, because our model has
an explicit spatial component and because we trace the locations
of all cells. We believe that the results obtained by deploying our
hybrid approach with accurate implementation of physical inter-
actions between cells reﬂect the versatility, extendibility, and
potential of our model as a computational tool that provides
feedback valuable to experimental and clinical studies.
Our research is greatly motivated by the sarcoma research at
Mofﬁtt Cancer Center. Preclinical sarcoma research at Mofﬁtt
Cancer Center has demonstrated promising results using small
molecule inhibitors of the cell cycle, namely the CDK inhibitor
dinaciclib and the WEE1 inhibitor MK1775. The latter has been
shown to abrogate the G2/M checkpoint forcing cells with DNA
damage to enter into unscheduled mitosis to undergo cell death,
often referred to as mitotic catastrophe (De Witt Hamer et al.,
2011). It has shown that this molecule also causes DNA damage
and leads to apoptosis, an unexpected ﬁnding suggesting activity
beyond affecting the G2/M checkpoint (Kreahling et al., 2012,
2013). MK1775 has broad activity across sarcoma subtypes and
lead to differentiation and necrosis in a xenograft model of
osteosarcoma (Kreahling et al., 2012). These agents are being
further explored preclinically and clinically in osteosarcoma and
other pediatric malignancies (NCT01748825, NCT01434316)
(Sampson et al., 2013). Sarcomas are heterogeneous, mesenchymal
tumors affecting both pediatric and adult populations (Ludwig and
Trent, 2008; Reed and Altiok, 2011). Approximately 10% of child-
hood cancer and 8% of young adult cancers are sarcomas, com-
pared to 1% of cancer incidence in people over 40 years of age.
Ewing sarcoma, osteosarcoma and rhabdomyosarcoma affect
about three quarter of all children with sarcomas whereas
liposarcoma, leiomyosarcoma, undifferentiated sarcoma, neuroﬁ-
brosarcoma, and synovial sarcoma represent some of the most
common sarcoma types in the adult population (Amankwah et al.,
2013; Reynoso et al., 2010). The treatment of nonmetastatic
sarcomas is frequently with curative intent with the use of multi-
modality therapy including surgery, radiation therapy with or
without anthracycline-based, and chemotherapy. However and
disappointingly, cure rates have only been very modestly
improved for metastatic disease and recurrent sarcomas. Multiple
attempts at increasing the doses of these conventional chemother-
apeutic agents have increased toxicity without improved efﬁcacy
(Thomas and Wagner, 2010). Thus, there is a pressing need to
develop novel therapies to improve outcomes in sarcoma patients.
Novel model systems, including mathematical and computational
models, which can recapitulate critical elements of tumor biology
would help speed up translation of basic research ﬁndings and
traditional bench experiments and perhaps guide translation
towards combinations of therapy, order of addition of therapies,
or optimal length of exposure for optimal anticancer effect.
Supplementary material related to this article can be found
online at http://dx.doi.org/10.1016/j.jtbi.2014.02.027.
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